AMACR Monoclonal Antibody

1. High expression of AMACR was not only a key adverse prognostic factor but also a potential therapeutic target in oral squamous cell carcinoma PMID:29725255
2. AMACR expression was studied in normal mucosa of the colon, adenomas with different degrees of dysplasia, colonic carcinomas, lymph nodes and liver metastases of colonic carcinomas. Expression was nearly absent in samples of normal mucosa, increased in both adenomas and carcinomas, decreased in lymph node metastases but was significantly increased in liver metastases. PMID:29179959
3. IMP3 has a similar specificity, but a better sensitivity, intensity, and extent of reactivity in comparison with AMACR, and may be used as an alternative to AMACR, in support of the diagnosis of BE-dysplasia and EAC PMID:26766126
4. As an adjunct to biopsy, AMACR and HMWCK have value for resolving diagnostically challenging cases PMID:28508828
5. Single nucleotide polymorphism in AMACR gene is associated with schizophrenia risk loci with potential implications for neurocognitive performance. PMID:28902459
6. Results show that AMACR expression is significantly high in patients with prostate cancer. PMID:29277318
7. High AMACR expression is associated with prostate cancer. PMID:28741117
8. AMACR staining was positively expressed in 86 of the prostate carcinoma cases and completely absent in remaining 12. PMID:28384107
9. Data show a significant association between Alpha-methylacyl-CoA racemase (AMACR) and ERG protein with prognostic implication in prostate cancer. PMID:27271990
10. AMACR is expressed in most of the chordomas but only in a minority of chondrosarcomas. AMACR may serve as IHC marker of chordoma with differentiating ability comparable to that of beta-catenin. PMID:26888362
11. AMACR transcripts were detected in all radical prostatectomy(RP)-prostate cancer and RP-Benign samples but not in non-cancerous cystoprostatectomy samples, which suggest a global increase of AMACR expression in cancerous prostates. PMID:26928323
12. AMACRwas not regulated in the white blood cells of multiple sclerosis patients PMID:26648339
13. study showed that 34betaE12 is the most appropriate negative marker to combine with alpha-methylacyl coenzyme A racemase as a positive marker for the diagnosis of prostate adenocarcinoma[34betaE12] PMID:20189848
14. The D175G and M9V polymorphisms of the AMACR gene are related to prostate cancer. The S201L polymorphism might be linked with prostate cancer risk. no association was observed between K277E or Q239H polymorphisms and susceptibility to prostate cancer. PMID:25773837
15. AMACR amplification is a mechanism driving increased mRNA and protein expression and conferring aggressiveness through heightened cell proliferation in gastrointestinal stromal tumors PMID:25473890
16. In diagnosis of ovarian clear cell carcinoma, AMACR is highly specific but suboptimally sensitive. PMID:25551297
17. Overexpressed AMACR in myxofibrosarcomas can be amplification-driven, associated with tumor aggressiveness, and may be relevant as a druggable target. PMID:25384383
18. Combination of p63 and AMACR is of great additional value in combating the morphologically suspicious cases and should be used on case to case basis especially in prostatic needle biopsies and small foci lesions. PMID:25313761
19. Our results suggest AMACR as an immunohistochemical marker for distinguishing malignant melanomas and dysplastic nevi from conventional melanocytic nevi. PMID:25149154
20. AMACR might be a potential prognostic marker for predicting early recurrence/metastasis of hepatocellular carcinoma after hepatectomy. PMID:25092674
21. The overexpression of AMACR in prostate cancer was not associated with dietary influences on phytanic acid. PMID:25307752
22. AMACR overexpression was identified as an important prognosticator and a potential therapeutic target in the future PMID:24833092
23. AMACR is a useful immunohistochemical marker for the differential diagnosis of solid pseudopapillary neoplasms of the pancreas. PMID:24675392
24. AMACR should be the first-line positive marker for confirmation of a diagnosis of minimal adenocarcinoma of the prostate. PMID:24705308
25. Genetic variations of AMACR are associated with the risk of sporadic prostate cancer that underwent radical prostatectomy in Koreans. PMID:24383053
26. Strong AMACR expression is associated with an increased risk of neoplastic progression in Barrett's esophagus. PMID:24004067
27. in the subgroup of papillary renal cell carcinoma both a higher grade and a presence of distant metastases were associated with a lower percentage of alpha-methylacyl CoA racemase (AMACR)expressing tumors. PMID:22009118
28. role of AMACR in drug metabolism, cancer and drug design PMID:23376124
29. Case Report: AMACR homozygous mutation responsible for adult onset alpha-methyl-acyl-CoA racemase deficiency. PMID:20821052
30. These findings indicate that AMACR expression is strongly associated with endometrial clear cell carcionma and displays a relatively robust diagnostic test performance. PMID:24119561
31. Overall disease-free survival tended to be worse in AMACR-positive patients, and in adenocarcinoma subgroup, it was significantly shorter PMID:23235347
32. ERG immunohistochemistry could be considered in a second round of immunostaining of select difficult cases of foamy gland carcinoma of the prostate with low AMACR expression. PMID:23797726
33. Of the cases of clear cell renal carcinoma there was immunoreactivity for alpha-methylacyl-CoA racemase and strong diffuse immuno-positivity for cytokeratin. PMID:23434146
34. Alpha methylacyl-COA racemase cannot discriminate hepatocellular carcinoma from liver cell dysplasiA, although it can separate both of them from nondysplastic lesions. PMID:22542076
35. The sensitivity and specificity of AMACR for the diagnosis of prostate adenocarcinoma and benign glands in Japanese patients are lower than those previously reported in Western countries. PMID:22593005
36. Our results indicate that alpha-methylacyl-coenzyme A racemase is a useful marker for distinguishing between grade 1 and grade 2 neuroendocrine tumours, and neuroendocrine carcinoma of the stomach PMID:22782380
37. High AMACR is associated with prostate cancer. PMID:22248277
38. Alpha-methylacyl-coenzyme A racemase expression is associated with mucin phenotypes of gastric neoplasia, particularly with the expression of CDX2 and MUC5AC. PMID:22078291
39. AMACR can be considered a more accurate marker than PTOV1 in the identification of high-grade prostatic intraepithelial neoplasia (HGPIN) and of prostate cancer. PMID:22507319
40. Our study showed that 34betaE12 is the most appropriate negative marker to combine with AMACR as a positive marker for the diagnosis of prostate adenocarcinoma. PMID:20189848
41. This report shows the first high-throughput screen for the discovery of novel AMACR inhibitors, characterizes the first nonsubstrate-based inhibitors, and validates that AMACR is a viable chemotherapeutic target in vitro. PMID:21441411
42. Overexpression of alpha-methylacyl-CoA racemase is associated with CTNNB1 mutations in hepatocellular carcinomas PMID:21457159
43. A combination of high molecular weight cytokeratin and alpha-methylacyl CoA racemase is of great value in combating the morphologically suspicious cases and significantly increasing the diagnostic accuracy in prostate cancer. PMID:21176184
44. The results suggest that AMACR may play a significant role in susceptibility to schizophrenia in male patients. PMID:20875727
45. Our data suggest that AMACR variants have better power than total AMACR in discriminating between CaP and adjacent normal tissue. These findings may be useful for the development of future diagnostic assays PMID:21195844
46. Examine P504S expressing circulating prostate cells as a marker for prostate cancer. PMID:20664974
47. AMACR shows promise as a marker to indicate indefinite dysplasia in Barrett's oesophagus. PMID:20636793
48. Results describe alpha-methylacyl CoA racemase (AMACR) expression in relation to various dysplasia phenotypes and clinicopathological parameters of sporadic colorectal adenomas. PMID:20503447
49. marker of differential diagnosis of kidney cancer PMID:20102405
50. The expression of AMACR is increased in benign sebaceous glands and sebaceous hyperplasia; with decreasing AMACR expression in tumors with less sebaceous differentiation PMID:19638170

Show More

Hide All

HGNC: 451

UNIGENE: Hs.508343

KEGG: hsa:23600

STRING: 9606.ENSP00000371517

OMIM: 214950